RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
RVL Pharmaceuticals plc reports 2022 executive compensation
By ExecPay News
Published: April 24, 2023
RVL Pharmaceuticals plc reported fiscal year 2022 executive compensation information on April 24, 2023.
In 2022, four executives at RVL Pharmaceuticals plc received on average a compensation package of $455K, a 52% decrease compared to previous year.
Average pay of disclosed executives at RVL Pharmaceuticals plc
Tina deVries, Former EVP, Research & Development, received $561K in total, which decreased by 19% compared to 2021.
Brian Markison, Chief Executive Officer, received a compensation package of $525K, which decreased by 63% compared to previous year. 100% of the compensation package, or $525K, was in salary.
James Schaub, Chief Operating Officer, earned $367K in 2022, a 56% decrease compared to previous year.
Christopher Klein, General Counsel, received $367K in 2022, which decreases by 55% compared to 2021.
Related executives
You may also like
Source: SEC filing on April 24, 2023.